Multi-omic profiling of lesions at autopsy reveals a plethora of resistance mechanisms present within individual patients with ovarian cancer. This highlights the extreme challenge faced in treating end-stage disease and underscores the need for new methods of early detection and intervention.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Iacobuzio-Donahue, C. A. et al. Nat. Rev. Cancer 19, 686–697 (2019).
Burdet, N. L. et al. Nat. Genet. https://doi.org/10.1038/s41588-023-01320-2 (2023).
Rose, P. G., Piver, M. S., Tsukada, Y. & Lau, T. S. Cancer 64, 1508–1513 (1989).
Güth, U. et al. Cancer 110, 1272–1280 (2007).
Nguyen, L., Martens, J. W. M., Van Hoeck, A. & Cuppen, E. Nat. Commun. 11, 5584 (2020).
Rights and permissions
About this article
Cite this article
Hernando, B., Macintyre, G. A medley of resistance in ovarian cancers. Nat Genet 55, 361–362 (2023). https://doi.org/10.1038/s41588-023-01303-3